Target populationThe Nuclear medicine service is addressed to the pediatric and adult population.
The Molecular Nuclear Medicine service is part of the diagnostic imaging department, where low-ionizing radioactive substances are used (which are not harmful to the patient) in the diagnosis and treatment of diseases.
Regarding diagnosis, gamma-radiation emitting radioactive substances are used in low doses for studies, and administered to the patient through the oral, intravenous or inhaled routes.
Beta and alpha radioactive substances are used for the treatment of various diseases, both benign and oncological. These are referred to as metabolic therapies , a radiopharmaceutical is injected exclusively in the target organs according to their metabolism.
Scintigraphy and PET/CT studies are performed with various radiopharmaceuticals according to the organ and pathology to be studied.
Nuclear medicine studies can be used at different stages of a disease: diagnosis, follow-up, response to treatment and suspected progression. Additionally, some procedures help in prognosis.
Studies performed include diseases such as cancer and benign diseases.
These studies can be performed for the pediatric and adult population.